Get the Stockscreener App
44.93
3.88%
1.68
After Hours:
45.50
0.57
+1.27%
Akero Therapeutics Inc stock is traded at $44.93, with a volume of 1.07M.
It is up +3.88% in the last 24 hours and down -6.94% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$43.25
Open:
$43.02
24h Volume:
1.07M
Relative Volume:
0.90
Market Cap:
$3.59B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-11.98
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+2.04%
1M Performance:
-6.94%
6M Performance:
+2.53%
1Y Performance:
+75.37%
1-Day Range:
$42.97
$45.09
1-Week Range:
$42.55
$45.37
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
44.93 | 3.46B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.37 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
468.58 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.20 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
763.52 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
335.67 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Adage Capital Partners GP L.L.C. Purchases New Shares in Akero Therapeutics, Inc. $AKRO - MarketBeat
PDT Partners LLC Sells 122,183 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. $AKRO Shares Acquired by Exome Asset Management LLC - MarketBeat
Akero Therapeutics, Inc. $AKRO Position Decreased by American Century Companies Inc. - MarketBeat
Nomura Holdings Inc. Makes New Investment in Akero Therapeutics, Inc. $AKRO - MarketBeat
What is HC Wainwright's Forecast for AKRO Q1 Earnings? - MarketBeat
Akero therapeutics (AKRO) CSO Rolph sells $552k in stock By Investing.com - Investing.com Canada
200,534 Shares in Akero Therapeutics, Inc. $AKRO Purchased by Eventide Asset Management LLC - MarketBeat
Fred Alger Management LLC Has $20.86 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
Is Akero Therapeutics Inc. a cyclical or defensive stock2025 Sector Review & Technical Entry and Exit Tips - Lancaster City Council
Treasury Yields: Can Akero Therapeutics Inc. maintain its current growth rateTrade Exit Report & Growth Oriented Trading Recommendations - Lancaster City Council
Akero Therapeutics, Inc. $AKRO Shares Sold by Alliancebernstein L.P. - MarketBeat
EcoR1 Capital LLC Takes Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Cubist Systematic Strategies LLC Has $7.08 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Analysts Offer Predictions for AKRO Q3 Earnings - MarketBeat
Quant Models Detect Momentum Reversal in Akero Therapeutics Inc.July 2025 Review & Daily Volume Surge Trade Alerts - beatles.ru
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Allostery Investments LP Takes $729,000 Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Can Akero Therapeutics Inc. disrupt its industryWeekly Profit Analysis & Precise Entry and Exit Recommendations - beatles.ru
What hedge funds are buying Akero Therapeutics Inc.July 2025 Highlights & Capital Efficiency Focused Strategies - beatles.ru
RSI Reset May Fuel Rebound in Akero Therapeutics Inc.Long Setup & Verified Short-Term Plans - beatles.ru
HighTower Advisors LLC Makes New $292,000 Investment in Akero Therapeutics, Inc. $AKRO - MarketBeat
Alkeon Capital Management LLC Lowers Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. $AKRO Shares Sold by Baker BROS. Advisors LP - MarketBeat
Redmile Group LLC Has $38.02 Million Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
How does Akero Therapeutics Inc. compare to its peersWeekly Market Report & High Return Trade Opportunity Guides - classian.co.kr
Candlestick signals on Akero Therapeutics Inc. stock todayMarket Rally & Community Verified Watchlist Alerts - Newser
Risk adjusted return profile for Akero Therapeutics Inc. analyzedPortfolio Performance Report & AI Based Trade Execution Alerts - Newser
Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $81.57 - MarketBeat
How cyclical is Akero Therapeutics Inc.’s revenue streamWeekly Market Summary & Real-Time Stock Entry Alerts - خودرو بانک
Is Akero Therapeutics Inc. in a consolidation phaseM&A Rumor & Free High Accuracy Swing Entry Alerts - خودرو بانک
Will Akero Therapeutics Inc. benefit from government policyJuly 2025 Trends & Community Trade Idea Sharing - خودرو بانک
Will Akero Therapeutics Inc. price bounce be sustainableShort Setup & Fast Gain Stock Trading Tips - Newser
Propel Bio Management LLC Sells 114,845 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Northern Trust Corp Buys 36,412 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - sharewise.com
Can Akero Therapeutics Inc. deliver alphaJuly 2025 Short Interest & Accurate Intraday Trading Signals - خودرو بانک
Is Akero Therapeutics Inc. a strong growth stockQuarterly Portfolio Review & Accurate Entry/Exit Alerts - خودرو بانک
How to interpret RSI for Akero Therapeutics Inc. stockQuarterly Portfolio Report & Growth Focused Entry Reports - Newser
Akero Therapeutics, Inc. $AKRO Shares Purchased by Long Focus Capital Management LLC - MarketBeat
Key resistance and support levels for Akero Therapeutics Inc.2025 Buyback Activity & Expert Approved Trade Ideas - Newser
Is Akero Therapeutics Inc. forming a reversal patternMarket Activity Recap & Free Fast Gain Swing Trade Alerts - Newser
Risk vs reward if holding onto Akero Therapeutics Inc.2025 Institutional Moves & Breakout Confirmation Alerts - Newser
Akero therapeutics COO Young sells $576k in shares By Investing.com - Investing.com UK
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - MSN
ADAR1 Capital Management LLC Raises Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):